19 June 2013
Keywords: genentech, advises, shareholders, reject, roche, per, share
Article | 02 March 2009
US biotechnology giant Genentech has advised its shareholders to reject the $86.50 per share offer made by Swiss drug major Roche.
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
2 March 2009
18 June 2013
© 2013 thepharmaletter.com